table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 hospitalized
COVID-19 severe or critically
anti-interleukin-6
Levilimab V.Lomakin ...
sarilumab sarilumab Sanofi phase 3 US REMAP-CAP sarilumab ARI-RAF ... sarilumab Sanofi phase 3 outside US
sarilumab high dose (400mg) Lescure ...
sarilumab low dose (200mg) Lescure ...
tocilizumab COVACTA ... Rashad Karakike ... Somers Pereira Talaschian Belhassen-Garc??a Mathilde CORIMUNO-TOCI-1 ... Hamed Sarhan Andrew REMAP-CAP ... Karampitsakos Sarhan MARIPOSA CORIMUNO-TOCI-ICU ... Biran Veiga NCT04377750 ... TOCI-RAF Study Group ... Rosas ... Rojas-Marte

7 studies excluded by filtering options 2

5123 Gritti et al., 2020 2300excludednot a RCTrisk of bias not avaialble
5366 Rimland, 2020 2300excludednot a RCTrisk of bias not avaialble
5494 BREATH-19 Study, 0 2300excludednot a RCTrisk of bias not avaialble
5523 Toniati, 2020 2990excludednot a RCTrisk of bias not avaialble
5526 Price, 2020 2130excludednot a RCTrisk of bias not avaialble
5632 Holt, 2020 2130excludednot a RCTrisk of bias not avaialble
5672 Klopfenstein, 2020 2134excludednot a RCThigh risk of bias

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons